About
About Shionogi
Who we are
Heritage
Global affiliates and locations
Shionogi BV - tax strategy
Transparency
Investor Relations
Grants and Donations
Sustainability
Innovation
Innovation
Our areas of focus
Our Partners
Drug Discovery
Antimicrobial Resistance
News
Investors
Careers
Contact
Europe
Worldwide
HOME
News
2022
03
ACTG and Shionogi Announce Progress on Global Phase 3 Trial of Novel COVID-19 Oral Antiviral Agent S 217622
Release
Medical News
2022/03/16
ACTG and Shionogi Announce Progress on Global Phase 3 Trial of Novel COVID-19 Oral Antiviral Agent S 217622